US Pharma MarketingThe post First patient dosed in Artelo’s Phase II DREAM study for glaucoma appeared first on Clinical Trials Arena.
First patient dosed in Artelo’s Phase II DREAM study for glaucoma
Artelo Biosciences has dosed the first patient in the Phase II DREAM study assessing ART27.13 as a potential treatment for people with glaucoma or ocular hypertension. The post First patient dosed in Artelo’s Phase II DREAM study for glaucoma appeared first on Clinical Trials Arena .
Artelo Biosciences has dosed the first patient in the Phase II DREAM study assessing ART27.13 as a potential treatment for people with glaucoma or ocular hypertension.
Source: Clinical Trials Arena